Driving Scripts and Improving AQ: How DeepIntent Outcomes Delivers for Pharma Advertisers

There are more than 20,000 prescription drugs approved for marketing by the Food and Drug Administration (FDA). And yet, they all have one big thing in common: Driving script performance is a goal of theirs.

Pharma advertisers need fast, transparent, actionable measurement. This provides timely insights and powers the automatic, real-time optimizations that enable them to influence and optimize their healthcare provider (HCP) and patient campaigns through the funnel. Ultimately, they must answer these questions: Are they reaching the right verified patients and HCPs? Are they meeting in a clinical setting? Are they writing and filling scripts?

Only DeepIntent Outcomes™—the industry’s fastest measurement solution based on clinical data—offers daily audience quality (AQ) and script lift metrics. These help pharma brands answer those questions and achieve their goals: driving script performance metrics such as total prescriptions (TRx) and new prescription starts (NPS); improving audience quality (AQ); and reaching the right verified patients and healthcare providers (HCPs), all while decreasing their cost-pers.

Driving Scripts and Improving AQ

With patented technology that links real-world clinical data with impression data, Outcomes’ machine learning algorithms automatically optimize campaigns toward AQ and script performance. The algorithms spend three or four weeks “learning” how to best reach the highest-value patients and HCPs, or those most likely to prescribe your brand, ultimately driving scripts. From there, ongoing machine learning and bid optimization maximize script volume at the lowest possible cost.

Outcomes is currently used across more than 1,200 campaigns by more than 115 brands. One of those brands is an antiviral medication used to treat symptoms of an infectious disease. Outcomes optimizations improved AQ for all audiences, including third-party segments onboarded from industry-leading data providers. That delivered 865% greater AQ vs. the disease prevalence in the U.S. population. Ads reached patients who were more likely to be condition sufferers, ultimately driving scripts. The campaign contributed to more than 2,400 incremental scripts.

To learn more, download Revolutionizing Healthcare Advertising: How DeepIntent Outcomes™ Delivers Exceptional Performance for Leading Pharma Brands, which also includes pharma brands’ success stories such as:

  • Increasing AQ by up to 164% throughout a campaign
  • Driving scripts by 154% with a combination of connected TV, online video, and display
  • Influencing 27% script lift within a campaign’s first 120 days
  • Growing verified patient reach while reducing cost-per-verified patient (CPVP) by 37%
  • And more!

More Insights

Chairs in front of a screen with the AdLab logo
Blog Post
As Said at AdLab: The Current State of Health Advertising from the Marketer’s POV
Healthcare marketers today are navigating rapid change. Reshaping the industry as we know it, new privacy laws and technologies like generative AI create an air...
Read More
Three panelists onstage
Blog Post
Integrated Campaigns: Marketing as the Ultimate Social Experiment
At last week’s AdLab Health Marketing Summit, DeepIntent assembled leaders from across the pharma, marketing, and ad tech industries to address our current moment of...
Read More
Chris Paquette giving a presentation in front of an audience
Blog Post
The Future of Personalization in Health Advertising: Our Top 3 Takeaways from AdLab
In the fast-paced world of health marketing, leaders are on the hunt for innovations that improve their campaigns and patient outcomes. They know that strengthening...
Read More